CSPC Pharmaceutical Group has been granted a patent for a compound III that acts as an LSD1 inhibitor, including a specific crystal form. This compound and its crystal form are intended for use in developing medications for diseases related to LSD1. GlobalData’s report on CSPC Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CSPC Pharmaceutical Group, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. CSPC Pharmaceutical Group's grant share as of July 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Lsd1 inhibitor compound and its crystal form
The granted patent US12024494B2 describes a novel crystal form A of compound III, characterized by specific X-ray powder diffraction patterns. The claims detail the precise 2? angles at which characteristic diffraction peaks occur, with claim 1 listing peaks at 4.72±0.2°, 14.24±0.2°, 16.28±0.2°, 17.14±0.2°, 20.72±0.2°, 21.78±0.2°, 23.98±0.2°, and 24.96±0.2°. Subsequent claims expand on this by including additional peaks and specific angles, culminating in claim 3, which identifies a comprehensive list of diffraction peaks, including those at 4.721°, 9.479°, and 37.637°. Furthermore, claims 4 and 5 introduce thermal analysis data, indicating a differential scanning calorimetry (DSC) curve with an exothermic peak onset at 194.66±3° C and a thermogravimetric analysis (TGA) curve showing a weight loss of 1.331% at 194.21±3° C.
In addition to the characterization of crystal form A, the patent outlines a method for treating lung cancer, specifically small cell lung cancer, by administering an effective amount of this crystal form. Claim 6 emphasizes the therapeutic application of crystal form A, while claim 7 narrows the focus to small cell lung cancer, indicating a potential clinical relevance for this compound. The detailed characterization and the proposed medical application suggest that this crystal form A may have significant implications in both pharmaceutical development and cancer treatment strategies.
To know more about GlobalData’s detailed insights on CSPC Pharmaceutical Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
